Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 30;11(13):3798.
doi: 10.3390/jcm11133798.

High-Sensitivity Cardiac Troponin T and the Diagnosis of Cardiovascular Disease in the Emergency Room: The Importance of Combining Cardiovascular Biomarkers with Clinical Data

Michele Golino  1   2 , Jacopo Marazzato  1   2 , Federico Blasi  1   2 , Matteo Morello  2   3 , Valentina Chierchia  1 , Cristina Cadonati  2   3 , Federica Matteo  1   2 , Claudio Licciardello  1   2 , Martina Zappa  1   4 , Walter Ageno  1   2 , Alberto Passi  1   2 , Fabio Angeli  1   4 , Roberto De Ponti  1   2
Affiliations

High-Sensitivity Cardiac Troponin T and the Diagnosis of Cardiovascular Disease in the Emergency Room: The Importance of Combining Cardiovascular Biomarkers with Clinical Data

Michele Golino et al. J Clin Med. .

Abstract

Background. Nowadays, it is still not possible to clinically distinguish whether an increase in high-sensitivity cardiac troponin (hs-cTn) values is due to myocardial injury or an acute coronary syndrome (ACS). Moreover, predictive data regarding hs-cTnT in an emergency room (ER) setting are scarce. This monocentric retrospective study aimed to improve the knowledge and interpretation of this cardiac biomarker in daily clinical practice. Methods. Consecutive adult patients presenting at the ER and hospitalized with a first abnormal hs-cTnT value (≥14 ng/L) were enrolled for 6 months. The baseline hs-cTnT value and the ensuing changes and variations were correlated with the clinical presentation and the type of diagnosis. Subsequently, multivariable models were built to assess which clinical/laboratory variables most influenced hospital admissions in the investigated population analyzed according to the final reason for hospitalization: (1) cardiovascular vs. non-cardiovascular diagnosis, and (2) ACS vs. non-ACS one. Results. A total of 4660 patients were considered, and, after a first screening, 4149 patients were enrolled. Out of 4129 patients, 1555 (37.5%) had a first hs-cTnT ≥14 ng/L, and 1007 (65%) were hospitalized with the following types of diagnosis: ACS (182; 18%), non-ACS cardiovascular disease (337; 34%) and non-cardiovascular disease (487; 48%). Higher hs-cTnT values and significant hs-cTnT variations were found in the ACS group (p < 0.01). The mean percentage of variation was higher in patients with ACS, intermediate in those with non-ACS cardiovascular disease, and low in those with non-cardiovascular disease (407.5%, 270.6% and 12.4%, respectively). Only syncope and CRP (OR: 0.08, 95% CI: 0.02−0.39, p < 0.01 and OR: 0.9988, 95% CI: 0.9979−0.9998, p = 0.02, respectively) or CRP (OR: 0.9948, 95% CI: 0.9908−0.9989, p = 0.01) and NT-proBNP (OR: 1.0002, 95% CI: 1.0000−1.0004, p = 0.02) were independent predictors of a cardiovascular disease diagnosis. On the other hand, only chest pain (OR: 22.91, 95% CI: 3.97−132.32, p < 0.01) and eGFR (OR: 1.04, 95% CI: 1.004−1.083, p = 0.03) were associated with the ACS diagnosis. Conclusions. Differently from the investigated biomarkers, in this study, only clinical variables predicted hospitalizations in different patients’ subgroups.

Keywords: acute coronary syndrome; cardiac troponin; diagnosis; emergency room; high sensitivity cardiac troponin; ischemic heart disease; myocardial injury; myocardial ischemia.

PubMed Disclaimer

Conflict of interest statement

R.D.P. has received lecture fees from Biosense Webster and Biotronik, and his institution has received an educational grant from Medtronic, Biotronik, Boston Scientific, Biosense Webster, Abbott. None for the other authors. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Figures

Figure 1
Figure 1
Flow-chart of the enrolled population.
See this image and copyright information in PMC

References

    1. Anderson J.L. ACCF/AHA guideline for the management of ST-elevation myocardial infarction: A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;127:4. doi: 10.1161/CIR.0B013E3182742CF6/-/DC2. - DOI - PubMed
    1. Amsterdam E.A., Wenger N.K., Brindis R.G., Casey D.E., Ganiats T.G., Holmes D.R., Jaffe A.S., Jneid H., Kelly R.F., Kontos M.C., et al. AHA/ACC guideline for the management of patients with non-st-elevation acute coronary syndromes: A report of the American college of cardiology/American heart association task force on practice guidelines. Circulation. 2014;130:e139–e228. doi: 10.1161/CIR.0000000000000134. - DOI - PubMed
    1. Ibanez B., James S., Agewall S., Antunes M.J., Bucciarelli-Ducci C., Bueno H., Caforio A.L.P., Crea F., Goudevenos J.A., Halvorsen S., et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur. Heart J. 2018;39:119–177. doi: 10.1093/eurheartj/ehx393. - DOI - PubMed
    1. Collet J.P., Thiele H., Barbato E., Barthélémy O., Bauersachs J., Bhatt D.L., Dendale P., Dorobantu M., Edvardsen T., Folliguet T., et al. ESC Guidelines for themanagement of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur. Heart J. 2020;42:1289–1367. doi: 10.1093/eurheartj/ehaa575. - DOI - PubMed
    1. Hygesen K., Alpert J.S., Jaffe A.S., Chaitman B.R., Bax J.J., Morrow D.A., White H.D. Fourth universal definition of myocardial infarction. Eur. Heart J. 2019;14:237–269. doi: 10.1093/eurheartj/ehy462. - DOI - PubMed